Figure 6

Inhibition of VEGF expression and angiogenesis by RBP2 knockdown in nude mice. (A) Tumorgenesis after injection of BGC-823 cells stably expressing RBP2 shRNA and control shRNA. (B) Tumor volume with RBP2 shRNA stable expression and controls. Data are median, with box edges as interquartile range and whiskers as the minimum and maximum values. **P < 0.01. (C) Growth curve with RBP2 shRNA stable expression and controls. **P < 0.01. (D) QRT-PCR analysis of RBP2 mRNA expression with RBP2 shRNA stable expression and controls. **P < 0.01 (E, F) Western blot analysis of RBP2 protein expression with RBP2 shRNA stable expression and the control. **P < 0.01. (G) Immunohistochemical staining for VEGF, CD31, CD34 and Ki67 in the control group (left panel) and RBP2 shRNA stable expression group (right panel). Representative images are shown. (H) Percentage positive area for CD31 and CD34 expression with the control and RBP2 shRNA stable expression determined immunohistochemically. **P < 0.01. (I) Percentage positive cells for VEGF and Ki67 with the control and RBP2 shRNA stable expression determined immunohistochemically. **P < 0.01.